Alcoholic liver disease

Alcoholic liver disease (ALD) refers to a range of progressive liver conditions caused by chronic and excessive alcohol consumption. One-third of the US population consumes alcohol above the recommended levels, increasing their risk of ALD. There are three stages of ALD, which may or may not occur sequentially. The first stage is typically asymptomatic and involves the development of (potentially) reversible alcoholic fatty liver. Continued alcohol consumption will lead to alcoholic hepatitis, the second stage, which often becomes chronic. Clinical findings in this stage include jaundice, fatigue, and fever. In the third and final stage, the patient develops alcoholic cirrhosis. Patient history, transaminase levels, and imaging studies are crucial for diagnosis and show different patterns of hepatic injury. Nonalcoholic steatohepatitis is a differential diagnosis and is currently regarded as an important cause of cirrhosis. Treatment of ALD requires complete cessation of alcohol use.

• Second most common cause of liver cirrhosis in the United States
• 28% of the US population exceeds the recommended limits of alcohol consumption.
• Lifetime prevalence of alcohol abuse: 18%
• ∼ 10–20% of heavy drinkers develop cirrhosis.

References:^[1][2][3][4]

Epidemiological data refers to the US, unless otherwise specified.

• Alcoholism is a very important cause of chronic liver diseases.
• Significant alcohol consumption
  • Men: > 210 g pure alcohol per week
  • Women: > 140 g pure alcohol per week

References:^[1][5]

• Hepatic degradation of ethanol to acetyl-CoA by alcohol dehydrogenase results in NADH excess (see breakdown of ethanol for more details) → ↑ NADH drives the formation of glycerol 3-phosphate (G3P) from dihydroxyacetone phosphate (DHAP) → ↑ in both G3P and fatty acids causes increased triglyceride synthesis in the liver and accompanying inflammation → steatohepatitis → chronic inflammation leads to hepatic fibrosis and sclerosis → portal hypertension and eventually cirrhosis

The stages of ALD may overlap and do not necessarily occur in sequence.

Alcoholic fatty liver (reversible)

• Mostly asymptomatic
• Some patients report feeling a sensation of pressure in the upper abdominal area.
• Hepatomegaly: soft in consistency
• Regresses after cessation of alcohol consumption
• Acute exacerbation with risk of hepatic failure is rare.

Alcoholic hepatitis (reversible in mild cases)

• Develops as a result of persistent, long-term alcohol use
• Nonspecific symptoms: nausea, loss of appetite, weight loss, low-grade fever with tachycardia
• Hepatomegaly with hepatic tenderness
• Jaundice
• Symptoms of withdrawal in alcohol-dependent individuals
• If portal hypertension ensues , splenomegaly, ascites, and/or variceal bleeding may develop.

Alcohol-related cirrhosis (irreversible)

• Final stage of ALD
• See “Clinical features” in cirrhosis.

References:^[6][7]

A history of alcohol abuse that correlates with typical laboratory and imaging findings is diagnostic of alcoholic liver disease.

Alcoholic fatty liver

• Laboratory tests
  • AST (aspartate aminotransferase) > ALT (alanine aminotransferase) (both ↑ ALT and ↑ AST)
  • ↑ GGT
  • ↑ Serum ferritin
  • Macrocytic anemia ^[8]
  • ↑ CDT(carbohydrate-deficient transferrin)
    • Most specific biomarker of heavy alcohol use regardless of the presence of liver disease
    • Levels elevated up to 6 weeks after abuse
• Imaging
  • Ultrasound
    • Mild hepatomegaly
    • Blood vessels cannot be visualized
    • ↑ Liver echogenicity because of steatosis: may be focal or diffuse
  • CT: ↓ liver attenuation

Imaging and laboratory studies in the case of alcoholic fatty liver will show a reversal of changes within a month if the patient abstains from alcohol!

Alcoholic hepatitis

• Laboratory tests
  • AST/ALT ratio > 2
    • ↑ AST: usually ≤ 500 U/L
    • ALT: normal or only mildly elevated
  • ↑ Alkaline phosphatase (ALP)
  • ↑ GGT
  • Impaired liver function
    • ↑ Bilirubin
    • ↓ Serum albumin
    • ↑ Prothrombin time
    • ↓ Cholinesterase
  • Macrocytic anemia, thrombocytosis , and absolute neutrophilic leukocytosis may be present.
  • ↑ Glutamate dehydrogenase (GLDH)
  • ↑ Ammonia
• Imaging
  • Ultrasound
    • Resembles alcoholic fatty liver; ; however, disease is typically diffuse
    • In addition to those findings: hepatomegaly and periportal edema
  • CT: ↓ liver attenuation

To remember that AST > ALT in alcoholic hepatitis, think of “Make a toAST with alcohol!

Alcohol-related cirrhosis

• See cirrhosis.
• Diagnosis confirmed by biopsy

References:^[9][10]

1. Alcoholic fatty liver
   • Accumulation of lipid droplets in the hepatocytes with gradual single cell necrosis within the lobules
2. Alcoholic hepatitis
   • Fatty liver with hydropic swelling and ballooning degeneration of hepatocytes within the lobules
   • Damaged hepatocytes typically contain Mallory bodies (hyaline inclusion bodies that contain keratin filaments and appear eosinophilic on H&E stain)
   • Immunoreaction: Neutrophilic granulocytes infiltrate hepatic tissue.
   • Fibrosis: pronounced excess formation of fibrous collagenous connective tissue with picture of "chicken wire-like network" in perivenous zones
     • Mechanical obstruction of the bile ducts → bile duct proliferates in connective tissue
3. Alcohol-related cirrhosis
   • Infiltration of lymphocytes
   • Massive accumulation of fat in hepatocytes
   • Formation of fibrous septa and regenerative nodules
   • Perivascular sclerosis of central veins (especially in the early stage)

Alcoholic fatty liver and mild alcoholic hepatitis may be reversible after cessation of alcohol intake. However, severe alcoholic hepatitis and cirrhosis are not reversible!

References:^{[11][12][13][14][15]}

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

• Descriptions:
  • NAFLD: non-alcohol related accumulation of fat in the liver cells
  • NASH: NAFLD with chronic inflammation and damage of liver cells
• Epidemiology
  • Very widespread
• Etiology
  • Obesity and/or type 2 diabetes (metabolic syndrome)
  • Medication (amiodarone, glucocorticoids, estrogen, antiretroviral drugs)
  • Parenteral nutrition, after resection of the small intestine and other gastrointestinal interventions
• Pathology
  • Hepatocellular lipid accumulation, mostly macrovesicular
  • Ballooning degeneration and necrosis
  • Inflammatory infiltrates, with scattered lymphocytes, neutrophils, and Kupffer cells
• Pathophysiology
  • ↑ Insulin resistance
    • ↑ Peripheral lipolysis
    • ↑ Triglyceride synthesis
    • ↑ Hepatic uptake of fatty acids
• Clinical presentation
  • Often asymptomatic
  • Hepatomegaly
  • May progress to cirrhosis
• Diagnostics
  • ↑ Transaminases (AST/ALT ratio < 1)
    • The reversal of the AST/ALT ratio to values > 1 may indicate progression to cirrhosis.
  • Rule out other causes of chronic hepatitis (e.g., heavy alcohol use, hepatitis B, hepatitis C, Wilson disease, autoimmune hepatitis, hemochromatosis, α1-antitrypsin deficiency)
• Therapy
  • Weight loss, optimization of diabetic treatment
  • Discontinue responsible medication
  • Studies suggest that ursodeoxycholic acid may have anti-inflammatory and anti-apoptotic effects in the liver and that vitamin E may decrease oxidative stress and improve aminotransferase levels in NASH patients.
• Complications: cirrhosis, hepatocellular carcinoma

NASH is a diagnosis of exclusion! Other causes of chronic liver disease must be ruled out by laboratory studies and/or biopsy.

A distinction between alcoholic and non-alcoholic fatty liver disease can only be drawn based on patient history!

There is more ALT than AST (AST/ALT < 1) if the Liver is infiltrated with Lipids.

References:^[16][17]

The differential diagnoses listed here are not exhaustive.

• Immediate cessation of alcohol use
• In some cases, glucocorticoids (e.g., prednisolone in severe disease)

References:^[7]

Decompensated cirrhosis

Mainly characterized by a constellation of clinical features resulting from decreased hepatic function:

• Portal hypertension
• Ascites
• Hepatic encephalopathy
• Coagulopathy
• Hepatorenal syndrome
• Hyperestrogenism
• End-stage liver disease

Other organ damage following chronic alcohol use

• Gastritis
• Malabsorption
• Chronic pancreatitis
• Wernicke-Korsakoff syndrome
• See alcohol use disorder.

Zieve syndrome

• Acute hemolytic anemia after excessive alcohol use over the course of several years, characterized by the following triad:
  • Alcoholic hepatitis
  • Jaundice
  • Hyperlipidemia

We list the most important complications. The selection is not exhaustive.

1. Wolf DC. Cirrhosis. In: Anand BS, Cirrhosis. New York, NY: WebMD. http://emedicine.medscape.com/article/185856. Updated: January 8, 2017. Accessed: March 25, 2017.
2. Mauriello LM, Gökbayrak NS, Van Marter DF, Paiva AL, Prochaska JM. An internet-based computer-tailored intervention to promote responsible drinking: findings from a pilot test with employed adults. Alcohol Treat Q. 2012; 30 (1): p.91-108. doi: 10.1080/07347324.2012.635528 . | Open in Read by QxMD
3. Hasin D, Keyes K. The epidemiology of alcohol and drug disorders. Springer New York ; 2010 : p. 23-49
4. Mathurin P, Bataller R. Trends in the management and burden of alcoholic liver disease. J Hepatol. 2015; 62 (1): p.S38-S46. doi: 10.1016/j.jhep.2015.03.006 . | Open in Read by QxMD
5. Flegel K, MacDonald N, Hebert PC. Binge drinking: all too prevalent and hazardous. Can Med Assoc J. 2011; 183 (4): p.411. doi: 10.1503/cmaj.110029 . | Open in Read by QxMD
6. O'Shea RS, Dasarathy S, McCullough AJ et al. Alcoholic liver disease. Am J Gastroenterol. 2009; 105 (1): p.14-32. doi: 10.1038/ajg.2009.593 . | Open in Read by QxMD
7. Heuman DM. Alcoholic Hepatitis. In: Anand BS, Alcoholic Hepatitis. New York, NY: WebMD. http://emedicine.medscape.com/article/170539. Updated: December 30, 2016. Accessed: March 25, 2017.
8. Robert T Means. Hematologic complications of alcohol use. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. https://www.uptodate.com/contents/hematologic-complications-of-alcohol-use.Last updated: January 22, 2020. Accessed: August 17, 2020.
9. Akunjee M, Akunjee N. CSA book: MRCGP CSA Symptom Solver: Clinical frameworks for the MRCGP CSA exam. Clinical Prep ; 2014
10. Diffuse Hepatic Steatosis. https://radiopaedia.org/articles/diffuse-hepatic-steatosis. Updated: January 1, 2017. Accessed: March 25, 2017.
11. Goljan EF. Rapid Review Pathology. Elsevier Saunders ; 2013
12. Tommolino E. Fatty Liver. In: Anand BS, Fatty Liver. New York, NY: WebMD. http://emedicine.medscape.com/article/175472. Updated: January 25, 2017. Accessed: March 25, 2017.
13. Sakhuja P. Pathology of alcoholic liver disease, can it be differentiated from nonalcoholic steatohepatitis?. World J Gastroenterol. 2014; 20 (44): p.16474–16479. doi: 10.3748/wjg.v20.i44.16474 . | Open in Read by QxMD
14. Orman ES, Odena G, Bataller R. Alcoholic liver disease: Pathogenesis, management, and novel targets for therapy. J Gastroenterol Hepatol. 2013; 28 (S1): p.77-84. doi: 10.1111/jgh.12030 . | Open in Read by QxMD
15. Torruellas C. Diagnosis of alcoholic liver disease. World J Gastroenterol. 2014; 20 (33): p.11684-11699. doi: 10.3748/wjg.v20.i33.11684 . | Open in Read by QxMD
16. Bayard M, Holt J, Boroughs E. Nonalcoholic fatty liver disease. Am Fam Physician. 2006; 73 (11): p.1961-1968.
17. Adams LA, Feldstein AE. Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Rev Gastroenterol Hepatol. 2010; 4 (5): p.623-635. doi: 10.1586/egh.10.56 . | Open in Read by QxMD
18. Herold G. Internal Medicine. Herold G ; 2014
19. Le T, Bhushan V, Chen V, King M. First Aid for the USMLE Step 2 CK. McGraw-Hill Education ; 2015